• Journal of Periodontal and Implant Science
• /
• 제32권1호
• /
• pp.187-198
• /
• 2002

The ultimate goal of periodontal therapy is the regeneration of periodontal tissue which has been lost due to destructive periodontal disease. To achieve periodontal regeneration, various kinds of methods have been investigated and developed, including guided tissue regeneration and bone graft. Bone graft can be catagorized into autografts, allografts, xenografts, bone substitutes. And materials of all types have different biological activity and the capacity for periodontal regeneration, but ideal graft material has not been developed that fits all the requirement of ideal bone graft material. Recently, bioactive glass that has been utilized in plastic surgery is being investigated for application in dental practice. But, there has not been any long-term assessment of bioactive glass when used in periodontal intrabony defects. The present study evaluates the long-term effects of bioactive glass on the periodontal regeneration in intrabony defects of human and the effect of plaqu control on long term treatment results after dividing patients into those who underwent 3-month regular check-up and those who didn't under go regular check-up The clinical effect on 74sites from 17 infrabony pockets of 11 patients were analyzed 36months after treatment. 51 sites which underwent regular check up were classified as the Follow-up group(F/U group), and 23 sites which did not undergo regular check up were classified as Non Follow-up group(Non F/U group). After comparing the probing depth, attachment loss, bone probing depth before and 36months after treatment, the following results could be concluded. 1. The changes of probing pocket depth showed a statistically significant decrease between after baseline and 36 months after treatment in F/U group(1.79${\pm}$0.68mm) and did no show astatistically significant decrease between after baseline and 36months after treatment in Non F/U group(0.61${\pm}$0.54mm) (P<0.05). 2. The changes of loss of attachment showed a statistically significant decrease between after baseline and 36 months after treatment in F/U group(1.44${\pm}$0.74mm) and did no show astatistically significant decrease between after baseline and 36months after treatment in Non F/U group(1.18${\pm}$1.54) (P<0.05). 3. The changes of bone probing depth showed a statistically significant decrease between after baseline and 36 months after treatment in both F/U(1.35${\pm}$0.28) and Non F/U group(0.78${\pm}$0.55mm) (P<0.05). The results suggest that treatment of infrabony defects with bioactive glass resulted in significan reduction of attachment loss and bone probing depth 36months after the treatment. The use of bioactive glass in infrabony defects, combined with regular check-up and proper plaque control generally shows favorable clinical results. This measn that bioactive glass could be a useful bone substitute.

• Journal of Acupuncture Research
• /
• 제19권1호
• /
• pp.135-146
• /
• 2002

Background and Purpose : This study shows the clinical effects on treatment with Rheumatoid arthritis using Aqua-acupuncture such as Ursi Fel Bovis Calculus and Cathami Flos that are known for which have anti-inflammatory and analgesic effects. Objective and Methods : This study has been carried out Aqua-acupuncture treatment such as Cathami Flos and Ursi Fel Bovis Calculus twice or three times a week with patients diagnosed as rheumatoid arthritis on 7 criteria of US Rheumatism Academy. Results : 1. If you see the sexual distribution, it shows the rates of male and female 1: 1.83. Age distribution shows as age ascend it shows high. 2. If you see the duration distribution, it shows chronic tendency in order of more than 6 months(63.3%), 2 to 5 months, and I month. 3. If you see the invaded distribution, it shows chronic tendency in order of hand(37 cases), wrist joint(34 cases), knee joint(32 cases), ankle joint(21 cases), elbow joint(16 cases), shoulder joint(14 cases), feet(14 cases), hip joint(9 cases), low back(6 cases), neck(4 cases). 4. Seeing the mean post-therapeutic index among groups on RA factor level distinction, it shows that 0-18(normal range) scored 89.0, 19-50 scored 94.8, 51-80 scored 101.2, 81-100 scored 97.3, 101-140 scored 102.4, above 141 scored 97.5. 5. Seeing the mean post-therapeutic index among groups on CRP level distinction, it shows that 0-0.4(normal range) scored 100, 0.5-1.0 scored 48.6, 1.1-2.0 scored 34.9, 2.1-3.0 scored 35.7, 3.1-4.0 scored 37.1, 4.1-5.0 scored 53.8, above 5.0 scored 70.4. 6. Seeing the mean post-therapeutic index among groups on ESR level distinction, it shows that 0-20(normal range) scored 48.6, 21-40 scored 57.5, 41-60 scored 59.2, 61-80 scored 59.2, above 81 scored 66.0. 7. If you see the satisfactory assesment after Aqua-acupuncture treatment such as Cathami Flos and Ursi Fel Bovis Calculus, Excellent is 11 cases, Good is 14 cases, and Moderate 5 cases. Conclusion : It will be better effects, if herbal medicine, moxibustion, and acupuncture are used together with Cathami Flos and Ursi Fel Bovis Calculus on rheumatoid arthritis as chronic inflammatory disease.

• Childhood Kidney Diseases
• /
• 제9권1호
• /
• pp.21-30
• /
• 2005

목 적 : 소아 신질환 환자들의 골상태 평가 및 골다공증의 유병률을 산출하고 스테로이드 치료 기간 및 용량과의 연관성을 알아본 후 예방과 치료를 위한 진료에 지침을 마련하고자 시행하였다. 방 법 1994년 이후 아주대병원 소아과에서 신장질환을 진단 받은 환자들을 대상으로 초음파 골량측정법으로 골밀도를 측정한 후 한국 소아표준골밀도치를 참조하여 골상태를 평가하였고 환자의 임상소견 및 생화학적 지표들의 평균값간에 차이가 있는 지를 알아보았다. 결 과 : 골밀도를 측정 받은 환자는 총44명이었다. 진단시 나이는 6.7$\pm$4.2세였고, 골밀도 측정시 역연령은 9.3$\pm$4.2세, 골연령은 8.2$\pm$4.6세로 골연령이 저하되어 있었다. 질환별로는 특발성 신증후군 24명(54.5%), Henoch Shonlein 신염 7명(15.9%), IgA 신병증 5명(13.6%), 역류성 신병증 2명(4.5%), 기타 5명(11.4%)이었다. 환아 13명(29%)의 골밀도가 감소되어 있었고 이중 5명(11%)은 골다공증 범주에 속하였다 질환별로는 특발성 신증후군 1명(4%), Henoch Shonlein 신염 2명(29%), 역류성 신병증 1명(50%), 기타 1명(23%)이었다. 정상, 골감소증, 골다공증 세 군으로 나누었을 때 골밀도 측정시점까지 스테로이드 투여기간은 각각 26.5$\pm$27.3개월, 32.1$\pm$39.6개월, 8.9$\pm$12.9개월이었고, 투여한 축적 용량은 221.7 $\pm$248.6 mg/kg, 177.1 $\pm$302.9 mg/kg, 49.9$\pm$45.5 mg/kg이었으며 세 군간에 유의한 차이는 없었다. 스테로이드의 투여기간을 장기간(6개월이상)과 단기간(6개월 미만)으로 나누어 비교했을 때 골밀도 측정값 및 골관련 생화학적 수치들은 차이가 없었다.결 론 : 초음파 골량측정법이 보편화되지 않았지만 정상 참고치와 비교가 가능하였으며 측정결과 골감소증은 29%, 골다공증은 11%로 상당수에서 골상태가 비정상임을 알 수 있었다. 본 연구에서는 스테로이드 사용기간 및 축적용량이 골상내의 변화에 특별한 영향을 미치지 않는 것으로 나타났다. 동일 환자들의 골상태의 변화관찰과 신질환 관련 골감소의 요인을 밝혀내기 위한 추가적인 연구가 필요할 것으로 사료된다.

• 한국국제농업개발학회지
• /
• 제30권4호
• /
• pp.347-356
• /
• 2018

GM작물은 세계적으로 재배면적이 지속적인 증가되고 있으며, 이로 인한 GM작물의 잠재적인 환경위해성에 대한 우려도 증가되고 있다. 현재까지 국내에서 GM작물의 상업적 재배는 되고 있진 않지만 GM작물의 안전성 평가를 위한 기술 개발은 크게 요구되고 있는 실정이다. 국내외적으로 다양한 GM작물의 유전자이동성 평가가 수행되어왔으나 화분 공급원인 GM벼의 개화기 차이에 의한 유전자 이동성 연구는 부족한 실정이다. 본 연구에서는 벼의 개화기 차이에 따른 비타민A 강화벼(PAC)로부터 모품종인 낙동벼와 중만생종인 일미벼, 조생종인 운광벼, 중생종인 대보벼, 통일형인 세계진미벼로의 화분매개에 의한 유전자 이동성을 평가하였다. 비타민A 강화벼(PAC)의 도입 유전자를 검출하는 PCR 분석을 통해 유전자 이동성 유무를 최종적으로 검증하였다. 총 파종된 종자수에 대한 교잡율은 개화기가 일치하는 낙동벼에서는 0.0007%, 개화기가 차이가 있는 일미벼, 운광벼, 대보벼, 세계진미벼에서는 0%로 나타났으며, 모든 교잡개체들은 비타민A 강화벼(PAC)에 근접한 2m 내에서 발견되었다. 화분 매개에 의한 비타민A 강화벼(PAC)의 유전자 이동 특성은 기존에 연구된 결과들과 비슷한 결과를 보였으며, 벼 재배품종간의 개화기 차이가 화분에 의한 교잡을 결정하는데 중요한 요인으로 작용하였다. 이에 벼 경작지의 기상 조건과 벼 품종간의 개화시기 중복 여부 등이 GM벼에 의한 일반 재배품종 및 잡초성벼로의 유전자 이동 최소화 기술 개발과 안전관리 기준 작성에서 주요 영향 요소들로 고려해야 한다.

• 대한본초학회지
• /
• 제27권2호
• /
• pp.1-16
• /
• 2012

Objective : To investigate the current status of prescription drugs in Oriental medical institutes and to draw up a future plan for the revitalization of Oriental medical health insurance, this survey has been performed. Method : The survey has been made with 321 doctors working at Oriental medical institutes in Daegu and Kyungbuk areas for a period of 3 month from June 1, 2010 until September 1, 2010. Result : 1. When it comes to the current status of the use of herbal drugs in Oriental Health insurance, most of doctors surveyed prescribe insurance drugs, and they prescribe insurance drugs to patients, who are less than 20% of total patients visiting their clinics. 2. The awareness of Herbal Health Care Drugs is investigated. When it comes to the understanding of the difference between insurance drugs(powder type drugs) and granular type drugs, doctors admit that they differ only in one aspect, whether or not their being covered by health insurance. Based on the survey results on the understanding of insurance coverage of granular type drugs, doctors, even though they long for granular type drugs to be accepted as insurance drugs, are worrying whether the number of outpatients might dwindle due to increased insurance co-payments. They also point out that the biggest obstacles in the expansion of the granular type drugs as insurance drugs are the lack of understanding of the government and the objection of the Health Insurance Review and Assesment service (HIRA) for fear of increased insurance claims. 3. Upon investigation on Oriental medicine doctors' understandings of herbal pharmaceutical industry, it is found that doctors' responses on pharmaceutical industry are not all positive ones('new product development and neglect of R&D infrastructure' and 'smallness of industry'). When it is investigated what area needs the greatest improvement in herbal pharmaceutical industry, 'securing sufficient capital, good manufacturing, and strengthening quality control', is the highest. 4. When it is asked what are the most needed in order to improve herbal health insurance medicine, responses such as 'the increase in the accessibility to and the utilization of Oriental medical clinics through the diversification of the means of prescriptions', 'the improvement of insurance benefits(cap adjustments)', 'increase the proportion of high quality medicinal plants', 'the ceiling of co-payments(deductible) at 20,000 won or more', 'expansion of the choices of formulations', 'formulational expansions of tablets and pills', and finally 'admittance and expansion of granular type drug as insurance drug' are the highest. 5. Upon investigating the general characteristics of the current status of the usage of Oriental health care herbal drugs, the followings are observed. First, the frequency of use of health insurance drugs by the doctors who use health insurance with general characteristics shows similar differences in case of total monthly sales amount (p<0.001), average number of daily patients (p<0.05). Secondly, as to the willingness of the expanded usage of insurance drugs, similar differences are observed in case of total monthly sales amount (p<0.05). 6. Upon investigating the general characteristics of the perception of Herbal health care drugs, the followings are observed. First, inspecting general characteristics and insurance claims due to increased co-payments(deductible amount) reveals similar differences in case of working period (p<0.01) and in case of total monthly sales amount (p <0.01). Secondly, inspecting general characteristics and the obstacles that hinder granular type drugs from being accepted as health care insurance drugs shows similar differences in case of working period (p<0.05). 7. Upon investigating the general characteristics of the understanding of Oriental Herbal pharmaceutical companies, the followings are observed. First, opinions on the general characteristics of pharmaceutical companies, when examined with variance analysis, shows similar differences in case of total monthly sales amount (p<0.05). Secondly, when opinions are examined on general characteristics and the problems of herbal pharmaceutical companies, similar differences are found in case of working period (p<0.01) and in case of total monthly sales amount (p<0.001). Lastly, opinions on the general characteristics and reforms of pharmaceutical companies, similar differences are observed in case of working period (p<0.001). 8. Upon investigating the general characteristics of the improvement of insurance Herbal drugs, the followings are observed. First, regarding general characteristics and insurance benefits, similar differences are observed in case of working period (p<0.05), in case of total monthly sales amount (p<0.05), and in case of average number of daily patients (p<0.01). Secondly, opinions on the general characteristics and the needs for the improvement of Herbal insurance drugs are examined in 5 different aspects, which are the approval of granular type drugs as insurance drugs, the expanded practices of the number of prescription insurance drugs, the needs of a variety of formulations, the needs of TFT of which numbers of Oriental medical doctors are members for the revision of the existing system, and the needs of adjusting the current ceiling of the fixed amount and the fixed rate. When processed by the analysis of variance, the results show similar differences in case of average number of daily patients (p<0.01). Conclusion : From the results of this study the first measures to take are, to reform overall insurance benefit system, including insurance co-payment system(fixed rate cap adjustment), to expand the number of the herbal drugs to be prescribed matching with insurance benefit accordingly, and to revitalize herbal medicine insurance system through the change of various formulations. In addition, it is recommended to improve the effectiveness of herbal medicine by making plans to enhance the efficacy of herbal medicine and by enabling small pharmaceutical companies to outgrow themselves.